MannKind Corporation (MNKD)

Market Cap	1.66B
Revenue (ttm)	301.74M
Net Income (ttm)	32.80M
Shares Out	306.83M
EPS (ttm)	0.11
PE Ratio	50.42
Forward PE	60.61
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,032,188
Open	5.38
Previous Close	5.37
Day's Range	5.38 - 5.54
52-Week Range	3.38 - 7.63
Beta	1.02
Analysts	Strong Buy
Price Target	10.80 (+99.45%)
Earnings Date	Nov 6, 2025

About MNKD

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of therapeutic products and services for endocrine and orphan lung diseases in the United States. It offers Afrezza Inhalation Powder, an inhaled insulin used to improve glycemic control in adults with diabetes; the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults; and Tyvaso DPI for the treatment of pulmonary arterial hypertension and pulmonary hypertension. The company’s product pipelin...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 28, 2004
• Employees: 407
• Stock Exchange: NASDAQ
• Ticker Symbol: MNKD
• Website: https://www.mannkindcorp.com

Analyst Summary

According to 5 analysts, the average rating for MNKD stock is "Strong Buy." The 12-month stock price target is $10.8, which is an increase of 99.45% from the latest price.

Price Target

$10.8

(99.45% upside)

Analyst Consensus: Strong Buy